Nuclear trafficking in health and disease

Current Opinion in Cell Biology

Volumn 28, Issue 1, 2014, Pages 28-35

  Mor, Amir ^a   White, Michael A ^a   Fontoura, Beatriz MA ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ACTIVE TRANSPORT; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOPLASM; HUMAN; METABOLISM; PHYSIOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; HUMANS; RNA, MESSENGER;

EID: 84893734957     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2014.01.007     Document Type: Review

References (57)

1. Wente S.R., Rout M.P. The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol 2010, 2:a000562.
2. Köhler A., Hurt E. Exporting RNA from the nucleus to the cytoplasm. Nat Rev Mol Cell Biol 2007, 8:761-773.
3. Natalizio B.J., Wente S.R. Postage for the messenger: designating routes for nuclear mRNA export. Trends Cell Biol 2013, 23:365-373.
4. Fribourg S., Braun I.C., Izaurralde E., Conti E. Structural basis for the recognition of a nucleoporin FG repeat by the NTF2-like domain of the TAP/p15 mRNA nuclear export factor. Mol Cell 2001, 8:645-656.
5. Ziegler E.C., Ghosh S. Regulating inducible transcription through controlled localization. Sci STKE 2005, 2005:re6.
6. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
7. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003, 3:102-109.
8. Reich N.C., Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006, 6:602-612.
9. Vandevyver S., Dejager L., Libert C. On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic 2012, 13:364-374.
10. Shen A., Wang Y., Zhao Y., Zou L., Sun L., Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009, 65:153-159. discussion 159-160.
11. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
12. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648-2655.
13. Yao Y., Dong Y., Lin F., Zhao H., Shen Z., Chen P., Sun Y.-J., Tang L.-N., Zheng S.-E. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009, 21:229-235.
14. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
15. Colombo E., Bonetti P., Lazzerini Denchi E., Martinelli P., Zamponi R., Marine J.-C., Helin K., Falini B., Pelicci P.G. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005, 25:8874-8886.
16. Falini B., Gionfriddo I., Cecchetti F., Ballanti S., Pettirossi V., Martelli M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood Rev 2011, 25:247-254.
17. Mutka S.C., Yang W.Q., Dong S.D., Ward S.L., Craig D.A., Timmermans P.B.M.W.M., Murli S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009, 69:510-517.
18. Shao C., Lu C., Chen L., Koty P.P., Cobos E., Gao W. p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 2011, 67:1369-1380.
19. Lapalombella R., Sun Q., Williams K., Tangeman L., Jha S., Zhong Y., Goettl V., Mahoney E., Berglund C., Gupta S., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120:4621-4634.
20. Turner J.G., Dawson J., Emmons M.F., Cubitt C.L., Kauffman M., Shacham S., Hazlehurst L., Sullivan D.M.A. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer 2013, 4:614-625.
21. Azmi A.S., Al-Katib A., Aboukameel A., McCauley D., Kauffman M., Shacham S., Mohammad R.M. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 2013, 98:1098-1106.
22. Schmidt J., Braggio E., Kortuem K.M., Egan J.B., Zhu Y.X., Xin C.S., Tiedemann R.E., Palmer S.E., Garbitt V.M., McCauley D., et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013, 10.1038/leu.2013.172.
23. Jeyasekharan A.D., Liu Y., Hattori H., Pisupati V., Jonsdottir A.B., Rajendra E., Lee M., Sundaramoorthy E., Schlachter S., Kaminski C.F., et al. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat Struct Mol Biol 2013, 20:1191-1198.
24. Culjkovic B., Topisirovic I., Skrabanek L., Ruiz-Gutierrez M., Borden K.L.B. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol 2005, 169:245-256.
25. Culjkovic B., Topisirovic I., Skrabanek L., Ruiz-Gutierrez M., Borden K.L.B. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006, 175:415-426.
26. Assouline S., Culjkovic B., Cocolakis E., Rousseau C., Beslu N., Amri A., Caplan S., Leber B., Roy D.-C., Miller W.H., et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009, 114:257-260.
27. Culjkovic-Kraljacic B., Baguet A., Volpon L., Amri A., Borden K.L.B. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep 2012, 2:207-215.
28. Chakraborty P., Wang Y., Wei J.-H., van Deursen J., Yu H., Malureanu L., Dasso M., Forbes D.J., Levy D.E., Seemann J., et al. Nucleoporin levels regulate cell cycle progression and phase-specific gene expression. Dev Cell 2008, 15:657-667.
29. Faria A.M.C., Levay A., Wang Y., Kamphorst A.O., Rosa M.L.P., Nussenzveig D.R., Balkan W., Chook Y.M., Levy D.E., Fontoura B.M.A. The nucleoporin Nup96 is required for proper expression of interferon-regulated proteins and functions. Immunity 2006, 24:295-304.
30. Tran D.D., Saran S., Dittrich-Breiholz O., Williamson A.J., Klebba-Färber S., Koch A., Kracht M., Whetton A.D., Tamura T. Transcriptional regulation of immediate-early gene response by THOC5, a member of mRNA export complex, contributes to the M-CSF-induced macrophage differentiation. Cell Death Dis 2013, 4:e879.
31. Capelson M., Liang Y., Schulte R., Mair W., Wagner U., Hetzer M.W. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 2010, 140:372-383.
32. Kalverda B., Pickersgill H., Shloma V.V., Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010, 140:360-371.
33. Köhler A., Hurt E. Gene regulation by nucleoporins and links to cancer. Mol Cell 2010, 38:6-15.
34. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., Luo J.-L., Patel D.J., Allis C.D. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009, 459:847-851.
35. Fontoura B.M., Blobel G., Matunis M.J. A conserved biogenesis pathway for nucleoporins: proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96. J Cell Biol 1999, 144:1097-1112.
36. Yarbrough M.L., White M.A., Fontoura B.M.A. Shaping the p53 response with nucleoporins. Mol Cell 2012, 48:665-666.
37. Singer S., Zhao R., Barsotti A.M., Ouwehand A., Fazollahi M., Coutavas E., Breuhahn K., Neumann O., Longerich T., Pusterla T., et al. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell 2012, 48:799-810.
38. Von Kobbe C., van Deursen J.M., Rodrigues J.P., Sitterlin D., Bachi A., Wu X., Wilm M., Carmo-Fonseca M., Izaurralde E. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 2000, 6:1243-1252.
39. Faria P.A., Chakraborty P., Levay A., Barber G.N., Ezelle H.J., Enninga J., Arana C., van Deursen J., Fontoura B.M.A. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 2005, 17:93-102.
40. Her L.S., Lund E., Dahlberg J.E. Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science 1997, 276:1845-1848.
41. Enninga J., Levay A., Fontoura B.M.A. Sec13 shuttles between the nucleus and the cytoplasm and stably interacts with Nup96 at the nuclear pore complex. Mol Cell Biol 2003, 23:7271-7284.
42. Zhang L., Das P., Schmolke M., Manicassamy B., Wang Y., Deng X., Cai L., Tu B.P., Forst C.V., Roth M.G., et al. Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. J Cell Biol 2012, 196:315-326.
43. Chakraborty P., Seemann J., Mishra R.K., Wei J.-H., Weil L., Nussenzveig D.R., Heiber J., Barber G.N., Dasso M., Fontoura B.M.A. Vesicular stomatitis virus inhibits mitotic progression and triggers cell death. EMBO Rep 2009, 10:1154-1160.
44. Satterly N., Tsai P.-L., van Deursen J., Nussenzveig D.R., Wang Y., Faria P.A., Levay A., Levy D.E., Fontoura B.M.A. Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proc Natl Acad Sci U S A 2007, 104:1853-1858.
45. Yarbrough M.L., Mata M.A., Sakthivel R., Fontoura B.M.A. Viral subversion of nucleocytoplasmic trafficking. Traffic 2013, 10.1111/tra.12137.
46. Kuss S.K., Mata M.A., Zhang L., Fontoura B.M.A. Nuclear imprisonment: viral strategies to arrest host mRNA nuclear export. Viruses 2013, 5:1824-1849.
47. Castelló A., Izquierdo J.M., Welnowska E., Carrasco L. RNA nuclear export is blocked by poliovirus 2A protease and is concomitant with nucleoporin cleavage. J Cell Sci 2009, 122:3799-3809.
48. Enninga J., Levy D.E., Blobel G., Fontoura B.M.A. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 2002, 295:1523-1525.
49. Nemeroff M.E., Barabino S.M., Li Y., Keller W., Krug R.M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell 1998, 1:991-1000.
50. Chen Z., Li Y., Krug R.M. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J 1999, 18:2273-2283.
51. Basu D., Walkiewicz M.P., Frieman M., Baric R.S., Auble D.T., Engel D.A. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 2009, 83:1881-1891.
52. Mata M.A., Satterly N., Versteeg G.A., Frantz D., Wei S., Williams N., Schmolke M., Peña-Llopis S., Brugarolas J., Forst C.V., et al. Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol 2011, 7:712-719.
53. König R., Stertz S., Zhou Y., Inoue A., Hoffmann H.-H., Bhattacharyya S., Alamares J.G., Tscherne D.M., Ortigoza M.B., Liang Y., et al. Human host factors required for influenza virus replication. Nature 2010, 463:813-817.
54. Das P., Deng X., Zhang L., Roth M.G., Fontoura B.M.A., Phillips M.A., De Brabander J.K. SAR based optimization of a 4-quinoline carboxylic acid analog with potent anti-viral activity. ACS Med Chem Lett 2013, 4:517-521.
55. Nousiainen H.O., Kestilä M., Pakkasjärvi N., Honkala H., Kuure S., Tallila J., Vuopala K., Ignatius J., Herva R., Peltonen L. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet 2008, 40:155-157.
56. Hodge C.A., Tran E.J., Noble K.N., Alcazar-Roman A.R., Ben-Yishay R., Scarcelli J.J., Folkmann A.W., Shav-Tal Y., Wente S.R., Cole C.N. The Dbp5 cycle at the nuclear pore complex during mRNA export I: dbp5 mutants with defects in RNA binding and ATP hydrolysis define key steps for Nup159 and Gle1. Genes Dev 2011, 25:1052-1064.
57. Folkmann A.W., Collier S.E., Zhan X., Ohi M.D., Wente S.R. Gle1 functions during mRNA export in an oligomeric complex that is altered in human. Dis Cell 2013, 155:582-593.